These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27196533)

  • 1. Immunogenicity of Anti-HLA Antibodies in Pancreas and Islet Transplantation.
    Chaigne B; Geneugelijk K; Bédat B; Ahmed MA; Hönger G; De Seigneux S; Demuylder-Mischler S; Berney T; Spierings E; Ferrari-Lacraz S; Villard J
    Cell Transplant; 2016 Nov; 25(11):2041-2050. PubMed ID: 27196533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes.
    Brooks AM; Carter V; Liew A; Marshall H; Aldibbiat A; Sheerin NS; Manas DM; White SA; Shaw JA
    Am J Transplant; 2015 Dec; 15(12):3239-46. PubMed ID: 26227015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of T and B Cell Epitopes to Predict the Risk of
    Sakamoto S; Iwasaki K; Tomosugi T; Niemann M; Spierings E; Miwa Y; Horimi K; Takeda A; Goto N; Narumi S; Watarai Y; Kobayashi T
    Front Immunol; 2020; 11():2000. PubMed ID: 32973806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Donor HLA Antibody Response After Pancreatic Islet Grafting: Characteristics, Risk Factors, and Impact on Graft Function.
    Pouliquen E; Baltzinger P; Lemle A; Chen CC; Parissiadis A; Borot S; Frimat L; Girerd S; Berney T; Lablanche S; Benhamou PY; Morelon E; Badet L; Dubois V; Kessler L; Thaunat O;
    Am J Transplant; 2017 Feb; 17(2):462-473. PubMed ID: 27343461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort.
    Ekong UD; Antala S; Bow L; Sese D; Morotti R; Rodriguez-Davalos M; Gan G; Deng Y; Emre SH
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):6-17. PubMed ID: 30777518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
    Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
    Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of HLA B- and T-cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation.
    Gramkow AM; Baatrup JH; Gramkow ET; Thiesson HC; Koefoed-Nielsen P
    Pediatr Transplant; 2024 Aug; 28(5):e14773. PubMed ID: 38808702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
    Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
    Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
    Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
    Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas-kidney transplantation.
    Malheiro J; Martins LS; Tafulo S; Dias L; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2016 Feb; 29(2):173-83. PubMed ID: 26404891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
    Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
    Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study.
    Kang ZY; Liu C; Liu W; Li D
    Transpl Immunol; 2023 Dec; 81():101930. PubMed ID: 37730183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.
    Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JSF; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
    Am J Transplant; 2018 Sep; 18(9):2274-2284. PubMed ID: 29464832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of two methods to detect donor-specific anti-HLA antibodies after kidney transplant.
    Gil BC; Kulzer ASS; de Moraes P; Toresan R; da Rosa Vicari A; Dos Santos Fagundes I; Merzoni J; Ewald GM; Cardone JM; Silva FG; Manfro RC; Jobim LF
    Transpl Immunol; 2018 Aug; 49():7-11. PubMed ID: 29577967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.